24 Results

Updated data from registration enabling NAVIGATOR trial of avapritinib for patients with PDGFRalpha, D842V-driven GIST and in second-, third- and fourth-line for other GIST patients. Blueprint Medicines

 Added 4 months ago

Blueprint Medicines Corporation announced updated data for the registration-enabling NAVIGATOR clinical trial of avapritinib, a potent and highly selective KIT...

Blueprint Medicines initiates Phase III trial of avapritinib to treat patients with advanced GIST.

 Added 8 months ago

Blueprint Medicines has dosed the first patient in the VOYAGER Phase III clinical trial, which is evaluating the safety and...

Induced pluripotent stem cells – a potential cancer vaccine

 Added 1 year ago

Induced pluripotent stem cells – a potential cancer vaccine

A new study from Stanford University may have found another use for iPS cells: priming the immune system to attack tumours.

World Cancer Day 2018

 Added 1 year ago

World Cancer Day 2018

UK NICE recommends use of Stivarga (regorafenib) in adults with gastrointestinal stromal tumours.- Bayer HealthCare.

 Added 1 year ago

The UK National Institute for Health and Care Excellence has backed Stivarga (regorafenib), from Bayer Healthcare, as a cost-effective option...

Successful Phase I trial of BLU 285 for gastrointestinal stromal tumors is basis for initiating Phase III trial in 2018.- BluePrint Medicines

 Added 1 year ago

Blueprint Medicines Corporation announced new Phase 1 clinical data and outlined registration plans for BLU 285, a potent and highly...

German Institute for Quality and Efficiency in Health Care suggests no additional benefit of Halaven (eribulin) in liposarcomas- Eisai

 Added 2 years ago

The German Institute for Quality and Efficiency in Health Care (IQWiG) has published a report which suggests that on formal...

Phase III data shows improvement in overall survival with Halaven (eribulin) vs dacarbazine in liposarcoma- Eisai

 Added 2 years ago

Halaven (eribulin), from Eisai, is an active agent against liposarcoma according to tumour subtype analyses of a Phase III trial...

Load more